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SUMMARY.-The growth of a CBA mammary adenocarcinoma has been
studied following transplantation to syngeneic and allogeneic recipients, with
particular reference to the susceptibilities of the primary and secondary
responses elicited by the tumour allografts, to impairment by whole-body
X-irradiation and by treatment with rabbit-anti-mouse lymphocyte serum.
In syngeneic recipients, the diameter oftumour implants increases linearlywith
time and there is no difference in the growth curves in females and in males.
Later tumour generations grow faster than earlier generations. In allogeneic
recipients, there is a relationship between the tumour diameter on day 21 (T)
and the dose of X-irradiation (D) administered before implantation:
T =0-028 D - 9*17
for early tumour generations (SMT4) but this is obscured for later generations
(SMT21). The primary response to tumour allografts was radiosensitive
whereas the secondary response was radioresistant. This radioresistance of
the secondary response persisted for at least 5 months after primary sensitiza-
tion. Unlike whole-body X-irradiation, treatment with rabbit-anti-mouse
lymphocyte serum suppresses both the primary and secondary responses to
tumourallografts. Thepossibilityisconsideredthatafterexposure to antigenic
stimulation, an immunologically reactive cell population is formed which is
radioresistant but sensitive to ALS, unlike the precursor cells from which this
population is derived, which are radiosensitive and sensitive to ALS.
IT has been suggested that malignant change is a relatively common occurrence
in animal cell populations (Rosenau and Moon, 1967) but that the establishment of
tumours is prevented, in many instances, by immunological mechanisms (Hum-
phrey and White, 1970). Attempts to utilize immunotherapy to control the
growth of tumours have been reported but the results of these are disappointing
(Woodruff and Symes, 1962; W.H.O. Tech. Rep. Ser., 1966). There is thus a need
for precise information about the immunological mechanisms which may influence
tumour growth.
A model has been proposed for the establishment of antibody-forming cell
populations by Albright and Makinodan (1965) and independently by Nossal
(1965). Two cell populations are postulated, one occupied by immunologically
uncommitted progenitor cells and the other by cells derived from the first com-
partment following antigenic stimulation. This model has proved useful in the
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study of the humoral response (Nettesheim, Makinodan and Williams, 1967;
Nettesheim and Williams, 1968) but its possible relevance to tumourregulation and
rejection has not been exploited.
A systematic comparison of the properties of the primary and secondary
responses to tumour allografts, and in particular their relative susceptibilities to
impairment, has therefore been undertaken in an attempt to elucidate the pro-
perties of the cell compartments involved in these responses. In the present
investigation the effects of whole-body X-irradiation and of rabbit-anti-mouse
lymphocyte serum have been compared using a technique which allows the growth
of solid tumour implants to be analysed conveniently (Riches and Thomas, 1970).
MATERIALS AND METHODS
Tumour
A spontaneous mammary adenocarcinoma has been used throughout this
investigation. This tumour which arises in females of the Birmingham CBA
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FIG. 1.-Spontaneous tumours in the Birmingham CBA mouse colony.
EXPLANATION OF PLATE
FIG. 2.-Spontaneous mammary adenocarcinoma arising in females of the Birmingham CBA
Mouse Colony (a, x 30; b, x 115). Metastases in the adrenal (c, X 115) and in the lung
(d, x 115).
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mouse colony has been serially transplanted in syngeneic females aged between
10 and 15 weeks. Spontaneous tumours are usually first observed at a mean age
of (564 ± 31) days (Fig. 1). The majority ofthe spontaneous tumours arising in
thispopulation offemales are mammaryadenocarcinomata. Thesearemoderately
well differentiated, exhibit a somewhat variable acinar pattern and show a quite
pronounced degree ofnuclear pleomorphism (Fig. 2). The transplanted tumour
has a histological appearance similar to that of the original tumour. Only one
tumour has been observed before 200 days, a mammary adenocarcinoma in a
neonatally thymectomized mouse, which was diagnosed at 84 days. Occasional
distantmetastasesareobservedinthelung(Fig. 2)andinlymphnodes. Metastases
were observed in theneonatally thymectomized mouse in the adrenal also (Fig. 2).
Tumour transplantation and growth measurement
The tumour is serially passaged in CBA females and transplanted to treated
mice using a Bashford needle trocar (supplied by Down Bros. Mayer & Phelps
Ltd.). Small tumour samples, weighing about 5 mg., have been implanted into
the right inguinal region.
The growth ofthe tumour implants can be conveniently followed by palpation
and comparison with steel spheres of graded size sewn into a piece of chamois
leather. The spheres increase in size in 1/16th inch units from 1/16th inch and the
mean tumour diameter is recorded in 1/16th inch units.
Irradiation
Mice have been irradiated in the radially disposed compartments of a perspex
cage, using an Andrex X-irradiation set (300 kVp, 5 mA., 5*0 mm. aluminium
plus 0 5 mm. copper filtration, dose-rate 60 rad./min.).
Rabbit-anti-mouse lymphocyte serum
Rabbit-anti-mouse lymphocyte serum (ALS) has been prepared using the two
pulse system ofLevey and Medawar (1966), in female New Zealand White rabbits.
The serum was stored at -20° C. and was not processed. Normal rabbit serum
(NRS) was also collected and stored. Mice were treated with 0 5 ml. aliquots of
ALS or NRS injected subcutaneously on days 0, 2, 4 and 6 after tumour trans-
plantation.
Growth of the CBA tumour in syngeneic hosts
Small samples of the tumour were transplanted to female and to male CBA
recipients aged between 10 and 16 weeks. Tumour growth was followed at two
daily intervals throughout the experiment. Growth of the tumour at different
transplant generations was compared.
Growth of the CBA tumour in X-irradiated allogeneic hosts
Groups offemale albino mice (CSI supplied by Scientific Products Farm, Ash),
weighing between 20 and 25 g., were exposed to doses of0, 300, 400, 500, 600 and
700 rad. ofwhole-body X-irradiation and given a tumour implant (4th generation
-SMT4). Thesize ofthetumourimplantswasmeasured 21 days afterirradiation.
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Further groups of mice were exposed to doses of 0, 300, 400, 500 and 600 rad.
of whole-body X-irradiation and the growth of a later tumour generation was
followed (21st generation-SMT21).
Mice that had already rejected an implant of the allogeneic mammary adeno-
carcinoma were divided into two groups 2 weeks after implantation: one group
was exposed to 600 rad. of whole-body X-irradiation and given a second tumour
implant, the other group was given a second tumour implant without preceeding
irradiation ofthe recipient. The growth of the tumours was followed.
CSI mice were given an implant of the CBA tumour and at intervals of 2 or
5 months received a second implant after exposure to 600 rad. of whole-body
X-irradiation. Tumour growth was also studied in groups ofirradiated CSI mice
of corresponding age, which had not previously rejected a tumour implant, in
order to ascertain its dependence upon host age and tumour generation.
Growthofthe CBA tumour inallogeneic hosts treated withrabbitanti-mouse lymphocyte
serum and normal rabbit serum
CSI mice were given a CBA tumour implant and injected with 0 5 ml. aliquots
ofALS or NRS on days 0, 2, 4 and 6 after implantation. Two groups ofmice that
had already rejected a CBA allogeneic tumour implant were given a second CBA
tumour implant immediately before treatment with ALS or NRS commenced.
The growth oftumour implants was followed.
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FIG. 3.-The growth of tumour implants in syngeneic recipients (standard errors are
indicated on this and all subsequent figures).
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RESULTS
Growth of the CBA tumour in syngeneic hosts
Implants ofthe CBA adenocarcinoma grow well in syngeneic female and male
recipients, aged between 10 and 16 weeks. No difference was observed between
the growth ofthe tumour in males and in females (P > 0 70 on days 10, 12 and 14,
Fig. 3). Earlier transplant generations (SMT2, spontaneous mammary tumour
transplant 2) grew rather more slowly than later generations (SMT17) (P < 0-001
between days 14 and 13). In all cases the tumour diameter increased linearly
with time following the sixth day after transplantation.
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FIG. 4.-Tumour diameter twenty-one days after implantation in irradiated
allogeneic recipients (tumour generation SMT4).
Growth of the CBA tumour in X-irradiated allogeneic hosts
The diameter of the tumour 21 days after implantation is related to the dose
of X-irradiation administered to the recipients of SMT4 (Fig. 4) by a relationship,
in the range 300 to 700 rad., ofthe form:
T 0-028D - 9-17
where T equals the tumour diameter on day 21 after transplantation and D the
dose of X-irradiation administered (regression coefficient 0-77, P < 0.001). In
mice receiving implants of later transplant generations, which grew much faster,
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there was however no difference in the rate oftumour growth after exposure ofthe
recipients to 400, 500 or 600 rad. Thus on day 14 there was no difference in the
sizes oftumours growing in mice exposedto these doses ofX-irradiation (P > 0 80,
Fig. 5). There was a marked difference between the growth ofthe tumour in these
groups and that in the untreated group in which the tumour was rejected in about
14 days or so (P < 0 001, Fig. 4).
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FiG. 5.-The growth of tumour implants in irradiated allogeneic recipients.
After 300 rad. ofwhole-body X-irradiation, the tumour grew well initially but
its growth rate was then retarded so that it reached a size of only 5-8 + 1.1
1/16th inch units on day 14following transplantation (P < 0.01) whenit was about
50% smaller than in the groups receiving high doses ofwhole-body X-irradiation.
The 14daytumour diameter ofthe 300 rad. group was largerthanthat in untreated
controls (P < 0.05).
In mice that had previously rejected an implant of the allogeneic tumour,
rejection of a second implant occurred briskly both in unirradiated controls and in
animals exposed to 600 rad. before implantation of the second allograft (Fig. 6).
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Eight days after irradiation and tumour transplantation there was a highly
significant difference between tumour diameters in the irradiated group and the
irradiated group that had already rejected an allogeneic tumour implant prior to
irradiation (P < 0001). This ability ofsensitized mice to reject a second implant
after exposure to 600 rad. of whole-body X-irradiation persisted for at least
5 months after implantation of the initial allograft (Fig. 7).
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FIG. 6.-The growth of tumour implants in irradiated sensitized allogeneic recipients.
r-
0
*c 8
-T
1-
a)
E
O4-
E
a)
E n-
4 8 12 16 20
days after transplantation
FIG. 7.-The growth of tumour implants in irradiated sensitized allogeneic recipients
at various time intervals after sensitization.
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Growth of the CBA tumour in allogeneic hosts treated with rabbit anti-Mouse lympho-
cyte serum or normal rabbit serum
The tumour grew well in mice treated with ALS but was rejected briskly in
controls treated with NRS (Fig. 8). Nine days after implantation there was a
significant difference between the tumour diameters of the ALS and NRS treated
mice (P < 0.01). Similarly in mice that had rejected an allogeneic tumour,
4 8 12 16
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FIG. 8.-The growth of tumour implants in allogeneic recipients treated with
anti-lymphocyte serum.
rejection ofa second implant did not occur following treatment with ALS. Fifteen
days after tumour transplantation there was a significant difference between the
tumour diameters ofthe sensitized mice treated with ALS and those treated with
NRS (P < 0.01). The differences in the growth rates of the primary and secon-
dary implants reflects the different growth rates of different tumour generations.
The size recorded for the tumours on day 15 in animals treated with NRS is
probably erroneous when it is likely that the enlarged inguinal nodes were being
palpated. Autopsy on day 16 revealed tumours of appreciable dimensions in all
of the mice treated with ALS but in none of the controls treated with NRS.
DISCUSSION
Following transplantation to syngeneic recipients the CBA mammary adeno-
carcinoma grows well and after serial transplantation the growthrate ofthe tumour
increases. Wexler, Orme and Ketcham (1968) who have reported similar findings
attributed this increase in growth rate to the loss oftumour antigens.
Following transplantation to allogeneic recipients the tumour is rejected within
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14 days or so. The tumour will, however, grow in allogeneic recipients which
have been exposed to whole-body doses of X-irradiation in excess of 300 rad.
before implantation. Rosenau and Moon (1967) using a chemically induced
tumour in syngeneic hosts have previously observed suppression of the primary
response after exposure to whole-body doses of X-irradiation. Whereas they
obtained maximum suppression after exposure to 300 rad., in the present investi-
gation the diameter of the tumour 21 days after implantation has been shown to
increase in a linear fashion with the dose of X-irradiation over the range from 300
to 700 rad. In experiments with more rapidly growing tumours from a later
transplant generation, however, the relationship is obscured.
A relationship between the dose of radiation administered and the skin-graft
survival time has already been reported by Brent and Medawar (1966). This is
of the form
1 1 ky x a
where x is the mean survival time, y is the radiation dose, a is the control survival
time and k is a constant.
Unlike the primary response to the tumour which is markedly radiosensitive,
the secondary response is radioresistant. This radioresistance persists for at least
5 months after sensitization. Thus animals exposed to 600 rad. of whole-body
X-irradiation 5 months after sensitization are still able to reject a second tumour
implant briskly. Tyan and Cole (1963) have shown that the secondary response
to skin allografts is also radioresistant.
In contrast to whole-body X-irradiation, rabbit anti-mouse lymphocyte serum
suppressed both the primary and secondary responses to tumour allografts. Skin
allograft rejection has been shown to be suppressed by ALS treatment (Levey and
Medawar, 1966) which also suppresses the development of immunity to tumour
cells (Deodhar, Crile and Schofield, 1968). We have now demonstrated that pre-
existent immunity is erased by treatment with ALS. Cerilli and Treat (1969)
have recently shown that the mortality of mice receiving either primary or
secondary tumour allografts is increased by ALS therapy.
In view ofthe ability ofALS to eradicate established immunity to tumours and
in the light of its increasing utilization in clinical practice (Starzl et al., 1967) it is
important to emphasize the potential hazards to patients receiving allografts
which may contain malignant cells (Martin et al., 1965; Zukoski et al., 1970) while
immunosuppression is being effected by ALS therapy.
No macroscopic metastases were observed during this series of experiments in
the mice treated with ALS. Other investigators using tumour cell suspensions
have described high incidences of metastasis in recipients treated with ALS
(Deodhar and Crile, 1969). Dissemination of cells is, however, much more likely
to occur after injection of cell suspensions than after the implantation of solid
tumour samples.
The model that has been proposed for the establishment of antibody-forming
cell populations (Albright and Makinodan, 1965; Nossal, 1965) can be usefully
considered in relation to tumour allograft rejection. In the intact mouse, any
necessary amplification and differentiation of the immunologically uncommitted
progenitor cells can occur sufficiently rapidly to effect tumour rejection within two
weeks whereas in the irradiated mouse, following doses above 300 rad., the response
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is not sufficiently rapid to effect tumour rejection after depletion ofthe progenitor
cell population.
Following exposure to the antigens of the tumour, the progenitor cell popula-
tion can respond either by enlarging or by giving rise to a population of immuno-
logically committed cells. A second implant will then be briskly rejected. It
has previously been demonstrated that spleen cells from sensitizedmice cantransfer
this enlarged or committed cell population to lethally irradiated recipients so that
they can reject an allogeneic tumour implant (Riches and Thomas, 1970). If the
progenitor cell pool is merely enlarged then the differential behaviour of X-irradia-
tion and ALS on the secondaryresponse would be due to a relative dose effect. If,
however, an immunologically committed cell compartment is established, the
present findings can beexplained bypostulating that the cells in this compartment
are, like the cells in the progenitor cell compartment, susceptible to damage by
ALS but unlike the cells in the progenitor cell compartment their effectiveness is
not impaired by whole-body doses ofX-irradiation up to 600 rad. As mice retain
their ability to reject tumour allografts after whole-body X-irradiation for at
least 5 months after sensitization then either the precursor pool must remain
enlarged or the committed cell population must persist for at least this period.
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